Amylyx Pharmaceuticals, Inc. stock soars to $35.11, but $350M offering clouds outlook

Amylyx Pharmaceuticals, Inc. stock surged to $35.11 on August 18 after its Phase 3 LUCIDITY trial for avexitide met all endpoints in post-bariatric hypoglycemia. Volume exceeded 23.6 million shares on the stock’s best day in nearly four years. However, a concurrent $350.0 million offering complicates the outlook.

Key takeaways

• AMLX closed at $35.11 on August 18 after the Phase 3 LUCIDITY trial for avexitide met its primary and all secondary endpoints in post-bariatric hypoglycemia.
• Trading volume exceeded 23.6 million shares, in what several outlets described as the stock’s best single-day performance in nearly four years.
• Amylyx concurrently announced a $350.0 million underwritten public offering of common stock, introducing immediate dilution risk on top of an already extended rally.
• Daily RSI14 stands at 82.74, while 1H RSI14 reads 87 and 15m RSI14 hits 88.36 — all deep in overbought territory.
• The 15-minute MACD has turned negative, signaling early intraday momentum exhaustion despite the higher-timeframe bullish structure.

Daily Chart: Amylyx Pharmaceuticals, Inc. Stock in a Bullish Regime With Extreme Overbought Readings

Amylyx Pharmaceuticals, Inc. stock remains in a structurally bullish trend across all major moving averages, but RSI readings above 82 and a breach of the upper Bollinger Band indicate the rally has become statistically extended.

… Continue reading the full article at the original source below.